Kahira Pharmaceuticals’ profits climb 153.5% in FY2023/24

Updated 8/8/2024 10:11:00 AM
Kahira Pharmaceuticals’ profits climb 153.5% in FY2023/24

Arab Finance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 153.5% year-on-year (YoY) rise in net profit after tax for the fiscal year (FY) of 2023/2024, according to the company’s financial statements filed to the Egyptian Exchange (EGX) on August 8th.

CPCI’s net profit after tax stood at EGP 246.132 million for the 12-month period ended June 30th, compared to EGP 97.092 million a FY earlier.

Sales surged by 34.9% YoY, hitting EGP 1.351 billion from EGP 1.001 billion.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Related News